(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

In the ad, McConaughey dines outdoors during a rainstorm because his booking app failed to adjust his reservations, ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

Welcome to the Novartis presentation at the 43rd JPMorgan ... Now when you look at the profile of the company today, I think some important points to highlight. One, we have 13 in-market ...

Daniel Ghinn spotlights how this pharma company is facilitating ... describing it as 'The official Twitter profile for news and information on Novartis-sponsored cancer trials in the US only ...